Clinical Trial Update: Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1 [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating whether a CCR5 coreceptor antagonist can influence HIV-1 latency and viral reservoirs has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Maraviroc (maraviroc)

Snippet

Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Conditions: HIV-1 | Phase 2 | Status: COMPLETED